Table 1: Results from the articles selected for this study.
| Reference | Authors, year and country | Therapeutic classes | Results basis | Study design | Cochrane risk of bias classification* |
|---|---|---|---|---|---|
| 18 | Léon et al., 2013 (England) | Cholinesterase inhibitors; statins: lipid-modifying agents; antioxidants; chelating agents | Clinical evidence | Narrative review | Unclear |
| 19 | Konrath et al., 2013 (Brazil) | Cholinesterase inhibitors; alkaloids | Not specific | Narrative review | High |
| 20 | McGuinness et al., 2013 (Ireland) | Statins: lipid-modifying agents | Phase III clinical trial | Systematic review (randomized with meta-analysis) | Low |
| 21 | Rubio-Perez and Morrilas-Ruiz, 2012 (Spain) | Anti-inflammatory agents; cytokines | Not specific | Narrative review | High |
| 22 | Appleby et al., 2013 (USA) | Agents for treating diabetes mellitus; nicotinic receptor agonists; phosphodiesterase inhibitors | Clinical evidence | Narrative review | Unclear |
| 25 | Pettenati et al., 2003 (Italy) | Cholinesterase inhibitors; immunomodulators; anti-inflammatory agents; NMDA receptor antagonists; antioxidants; phospholipase A2 inhibitors; nootropic drugs without elucidated mechanism of action for Alzheimer's disease; hormone therapy agents; chelating agents | Clinical evidence | Narrative review | Unclear |
| 26 | Sun et al., 2012 (China) | Cholinesterase inhibitors; muscarinic agonists; immunomodulators; anti-inflammatory agents; statins: lipid modifying agents; antioxidants; chelating agents; antihypertensive agents | Clinical evidence | Narrative review | Unclear |
| 27 | Yoo and Park, 2012 (Korea) | Terpenoids; antioxidants | Not specific | Narrative review | High |
| 28 | Dodel, 2013 (Germany) | Immunomodulators | Clinical evidence | Narrative review | Unclear |
| 29 | Mikulka et al., 2014 (USA) | Immunomodulators; secretase inhibitors; Inhibitors or modulators of beta and gamma-secretase | Phases I, II and III clinical trial | Systematic review (with clinical trial) | Low |
| 30 | Shukla et al., 2012 (USA) | Immunomodulators; cyclin kinase-5 dependent modulators | Not specific | Narrative review | High |
| 31 | Doody et al., 2014 (Germany) | Immunomodulators | Phase III clinical trial | Randomized clinical trial (double blind) | Low |
| 32 | Salloway et al., 2014 (USA) | Immunomodulators | Phase III clinical trial | Randomized clinical trial (double blind) | Low |
| 33 | Enciu and Popescu, 2013 (Romania) | Anti-inflammatory agents | Clinical evidence | Narrative review | Unclear |
| 34 | Feng and Wang, 2012 (China) | Anti-inflammatory agents; antioxidants; phospholipase A2 inhibitors | Not specific | Systematic review | High risk of bias |
| 35 | Wolfe, 2012 (USA) | Anti-inflammatory agents; Inhibitors or modulators of beta and gamma-secretase; chelating agents | Clinical evidence | Narrative review | Unclear |
| 36 | Ghosh et al., 2012 (USA) | Inhibitors or modulators of beta and gamma-secretase | Phase II clinical trial | Narrative review | Low |
| 37 | Hopkins, 2011 (USA) | Inhibitors or modulators of beta and gamma-secretase | Phase III Clinical trial | Short report | Unclear |
| 38 | Piccinni et al., 2013 (Italy) | Inhibitors or modulators of beta and gamma-secretase | Not specific | Narrative review | High |
| 39 | Eschecerria et al., 2012 (USA) | Nicotinic receptor agonists | Clinical evidence | Narrative review | Unclear |
| 40 | Freiherr et al., 2013 (Germany) | Agents for treating diabetes mellitus | Clinical evidence | Narrative review | Unclear |
| 41 | Morris and Burns, 2012 (USA) | Agents for treating diabetes mellitus | Clinical evidence | Narrative review | Unclear |
| 42 | Xu et al., 2015 (China) | Agents for treating diabetes mellitus | In vitro, in laboratory | Experimental study | High |
| 43 | Papadopoulos et al., 2013 (Canada) | Agents for treating diabetes mellitus | In vivo, in laboratory | Experimental study | High |
| 44 | Fukasawa et al., 2012 (Japan) | Retinoids | In vivo, in laboratory | Experimental study | High |
| 45 | Wong et al., 2013 (USA) | Statins: lipid-modifying agents | Not specific | Systematic review (randomized with meta-analysis) | Unclear |
| 46 | Calcul et al., 2012 (USA) | Polyphenols | Clinical evidence | Narrative review | Unclear |
| 47 | García-Osta et al., 2012 (Spain) | Phosphodiesterase inhibitors | Clinical evidence | Narrative review | Unclear |
| 48 | Evans et al., 2014 (USA) | Antioxidants; NMDA receptor antagonists | Phase III clinical trial | Randomized controlled clinical trial | Low |
| 49 | Revett et al., 2013 (Canada) | Antioxidants; NMDA receptor antagonists | Not specific | Narrative review | High |
| 50 | Kellermann et al., 2011 (Germany) | Antioxidants | Phase III clinical trial | Systematic review (randomized with meta-analysis) | Low |
| 51 | Freund Levi et al., 2014 (USA) | Antioxidants | Phase II clinical trial | Randomized controlled clinical trial | Low |
| 52 | Sun et al., 2012 (USA) | Phospholipase A2 inhibitors | Not specific | Narrative review | High |
| 53 | Koliaki et al., 2012 (Greece) | Nootropic drugs without elucidated mechanism of action for Alzheimer's disease | Phase III clinical trial | Randomized controlled clinical trial | Low |
| 54 | Maki and Henderson, 2012 (USA) | Hormone therapy agents | Randomized clinical trial | Narrative review | Low |
| 55 | Anekonda and Quinn, 2011 (Canada) | Antihypertensive agents | Clinical trials | Narrative review | Low |
| 56 | Valenzuela et al., 2012 (Australia) | Antihypertensive agents | Randomized controlled clinical trial | Narrative review | Low |
*We used the classification criteria of the Cochrane risk of bias to access the quality of the articles. In the case of review articles, the results from the selected articles were accessed in order to ascertain the evidence that was present in the kind of study that generated the results. Consequently, the Cochrane classification was made based on this evidence.